Financial Data and Key Metrics Changes - In Q1 2025, the company's revenue was $20.5 million, representing a 42% year-over-year growth, with a gross margin of 88% [5][24][25] - The company has maintained steady growth over the past eight to nine quarters, with no quarter showing lower revenue than the previous one [24] Business Line Data and Key Metrics Changes - The business model consists of 25% revenue from SaaS (subscription fees for the algorithm) and 75% from disposable headbands used for EEG monitoring, indicating a strong recurring revenue stream [25][27] - The company is currently focused on the seizure management market, which has a total addressable market (TAM) of $2 billion in the US [4][27] Market Data and Key Metrics Changes - The company currently holds only 2-3% of the US seizure detection market, indicating significant growth potential in the coming years [27] - The company is expanding its product offerings to include pediatric patients, having received FDA clearance for its seizure detection algorithm for ages one and older [28][29] Company Strategy and Development Direction - The company aims to make EEG a new vital sign in ICU settings, expanding its applications beyond seizure detection to include delirium and stroke triage [30][31] - The company is investing in its future pipeline, including ongoing studies for stroke detection and regulatory pathways for delirium detection [31] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of early detection and treatment in improving patient outcomes, particularly in acute care settings [11][12] - The company is focused on addressing unmet clinical needs in the acute care market, particularly for seizure management [3][4] Other Important Information - The company has a strong pipeline involving EEG signals and AI for indications beyond seizure management [4] - The company has published evidence showing significant reductions in length of stay and over-administration of anesthesia medication due to its technology [22] Q&A Session Summary Question: What is the company's growth strategy in the seizure detection market? - The company plans to maintain a laser focus on the seizure management market in the US, which has a significant growth opportunity given its current market share [27] Question: How does the company plan to expand its product offerings? - The company is working on expanding its seizure detection algorithm to younger populations and is also exploring applications for delirium and stroke detection [28][30]

Financial Data and Key Metrics Changes - Revenue for Q4 2024 was $18.5 million, reflecting a 41% growth compared to $13.1 million in Q4 2023 [31] - Full-year revenue totaled $65.4 million, representing a 45% growth over 2023 [33] - Gross margin for Q4 2024 was 88%, up from 85% in the prior year, while full-year gross margin was 87%, compared to 84% in 2023 [34][35] - Net loss for Q4 2024 was $12.6 million, or a loss of $0.40 per share, compared to a loss of $8.3 million, or a loss of $1.53 per share in Q4 2023 [36] Business Line Data and Key Metrics Changes - Product revenue for Q4 2024 was $14.1 million, a 41% increase from $10.0 million in Q4 2023 [32] - Subscription revenue for Q4 2024 was $4.4 million, representing a 40% increase from $3.1 million in Q4 2023 [32] - Active accounts increased to 529 as of December 31, 2024, an increase of 25 accounts during the quarter [16] Market Data and Key Metrics Changes - The company estimates there are 6,000 acute care facilities in the U.S. that could benefit from its offerings, with plans to target approximately 5,500 remaining prospective accounts [17] - The company is focused on expanding its market presence within the current $2 billion market in the U.S. for seizure detection and management in acute care settings [29] Company Strategy and Development Direction - The company aims to maintain its focus on commercial growth and expand its R&D pipeline, with a goal of becoming the standard of care for seizure management in acute care settings [22] - Plans for 2025 include expanding the account acquisition team to 55 territory managers and increasing awareness of the clinical and economic benefits of rapid EEG monitoring [21] - The company envisions expanding its product indications beyond seizure detection, including developing algorithms for delirium and stroke detection [25][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven and highlighted the strength of the balance sheet following a successful IPO [41] - The company anticipates total revenue for 2025 to be in the range of $81 million to $85 million, representing annual growth of 24% to 30% over 2024 [37] - Management noted that while accelerated initiatives may not drive immediate revenue, they are expected to have long-term impacts [40] Other Important Information - The company has received breakthrough device designation from the FDA for its delirium detection algorithm, with plans to submit an application later this year [25] - The transition to operating as a public company has increased stock-based compensation costs, expected to contribute approximately $15 million to operating expenses for the full year 2025 [41] Q&A Session Summary Question: Can you elaborate on the guidance for this year and the underlying assumptions? - Management indicated that guidance reflects continued investment in sales infrastructure, which is expected to accelerate growth in 2026 and beyond [46] Question: What are your thoughts on gross margin and OpEx spend in 2025? - Management noted that gross margins are expected to normalize in the mid to high 80% range due to increased tariffs and that R&D expenses are expected to increase by 40% to 60% year-over-year [54][56] Question: Can you provide updates on the stroke opportunity and the algorithm development? - Management expressed satisfaction with the progress in the stroke trial and plans to expand enrollment speed to gather more data for algorithm training [70] Question: How do you see utilization picking up with the new indications? - Management explained that the new indications will work synergistically to help doctors differentiate between various neurological conditions, enhancing overall patient care [83]